Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Biotechnologia

Mr. Anand  Reddi

Vice President and Head of Corporate Strategy & External Affairs & Engagement

Mr. John W. Rakow J.D.

Senior Vice President & General Counsel

Ms. Dena  House

Chief People Officer

Mr. Heikki  Jouttijarvi

Senior Vice President of Manufacturing & Supply Chain Management and Head of Technical Operations

Dr. R. Andrew Ramelmeier Ph.D.

Chief Technology Officer

Dr. Laurent  Fischer

President, Chief Executive Officer & Director

Dr. Romuald  Corbau Ph.D.

Chief Scientific Officer

Ms. Carla  Fiankan

Senior Vice President of Regulatory Affairs

Ms. Linda M. Rubinstein M.A.

Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer

Mr. Michael  Steel

Senior Vice President of Quality

Nazwa	Kapitalizacja rynkowa
Sorrento Therapeutics, Inc.	0M
Maravai LifeSciences Holdings, Inc.	0M
Comera Life Sciences Holdings, Inc.	0M
Gubra A/S	0M
CytoTools AG	0M
Shanghai Haohai Biological Technology Co., Ltd.	0M
Purple Biotech Ltd.	0M

Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc. Lista konkurentów

Główni konkurenci